Princess of Wales reflects on her recovery, visits the Royal Marsden Hospital to thank medical staff and announce new role as joint patron of the cancer unit.
Kate, the Princess of Wales, has announced she is in remission after undergoing a course of preventative chemotherapy following abdominal surgery in 2024. The 43-year-old royal expressed her relief in a statement on Tuesday, acknowledging the difficult journey of cancer treatment and the support she had received.
Kate was diagnosed with an unspecified form of cancer last year, and after completing her chemotherapy in September, she has now focused on her recovery.
Visiting the Royal Marsden Hospital in London, where she had received her treatment, Kate met with both patients and medical staff.
She thanked them for the exceptional care she had received and spoke of the toll her illness had taken on her family, especially her husband,
Prince William, and their three children.
During her visit, Kate also revealed that she and
Prince William have become joint patrons of the Royal Marsden, furthering their longstanding commitment to cancer care.
Reflecting on her experience, Kate shared her gratitude for the care she had received, saying, 'The care and advice we have received throughout my time as a patient has been exceptional.' The princess noted that adjusting to a ‘new normal’ after a cancer diagnosis is challenging, but expressed hope for a fulfilling year ahead.
This visit marked her first solo public appearance since returning to her official duties.
Kate’s health battle had a significant emotional impact on her family, with William describing the past year as ‘brutal,’ compounded by the news of King Charles undergoing cancer treatment.
Buckingham Palace has reported that the King’s treatment is progressing positively.
Kate’s latest visit and her message of gratitude highlight the importance of family support and the role of medical professionals during difficult times.
The princess’s involvement with the Royal Marsden also marks a personal and public commitment to advancing cancer research and care.